CJS Securities analyst Daniel Moore downgrades John Wiley & Sons (NYSE:WLY) from Market Outperform to Market Perform.
60 Degrees Pharma Announces IRB Approval Of Phase IIA Study To Evaluate Tafenoquine For Babesiosis, An Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled By FDA To January 17, 2024
Investigational Review Board (IRB) approval has been granted for 60 Degrees Pharma's double-blind, placebo-controlled study to investigate tafenoquine for treatment of hospitalized babesiosis
